💾 Archived View for spam.works › mirrors › textfiles › drugs › shulgbib.drg captured on 2023-11-14 at 09:33:13.
⬅️ Previous capture (2023-06-14)
-=-=-=-=-=-=-
Subject: The End of Psychedelic Exploration - from Slothrop Homage To: Shulgin's Psychedelic Publications Alexander Shulgin is the worlds foremost developer and explorer of psychedelic drugs. He has been, and remains, a prolific writer. His publications provide a great introduction to the diverse world of psychedelics, and provide and inspiration for psychedelic exploration. However, Shulgin has informed me that the publishing of any human data on new compounds had to stop abruptly with the enactment of the Analogue Drug Bill in 1986. This particular bit of obscenity makes the generation, or even the attempted generation, of any altered state of consciousness a felonious act. The continuing publication of experimental results in the medical and scientific literature is now totally impossible. For this reason I think it is worthwhile to provide a complete list of his psychedelic publications. They are well referenced, and can lead to much other psychedelic literature. Shulgin crossed the diamond with the pearl and gave birth to all forms of light: "It is early morning now. Slothrop's breath is white on the air. He is just up from a dream. Part I of a poem, with woodcuts accompanying the text - a woman is attending a dog show which is also, in some way, a stud service. She has brought her Pekingese, a female with a sickeningly cute name, Mimsy or Goo-Goo or something, here to be serviced. She is passing the time in a garden setting, with some other middle-class ladies like herself, when from some enclosure nearby she hears the sound of her bitch, coming. The sound goes on and on for much longer than seems appropriate, and she suddenly realizes that the sound is her own voice, this interminable cry of dog-pleasure. The others, politely, are pretending not to notice. She feels shame, but is helpless, driven now by a need to go out and find other animal species to fuck. She sucks the penis of a multicolored mongrel who has tried to mount her in the street. Out in a barren field near a barbed-wire fence, winter fires across the clouds, a tall horse compels her to kneel, passively, and kiss his hooves. Cats and minks, hyenas and rabbits, fuck her inside automo- biles, lost at night in the forests, out beside a waterhole in the desert. "As Part II begins, she has discovered she's pregnant. Her husband, a dumb, easygoing screen door salesman, makes an agreement with her: her own promise is never stated, but in return, nine months from now, he will take her where she wants to go. So it is that close to the end of her term he is out on the river, and American river, in a rowboat, hauling on the oars, carrying her on a journey. The key color in this section is violet. "Part III finds her at the bottom of the river. She has drowned. But all forms of life fill her womb. 'Using her as mermaid' (line 7), they trans- port her down through these green river-depths. 'It was down, and out again./ Old Squalidozzi, ploughman of the deep,/ At the end of his day's sowing/ Sees her verdigris belly among the weeds' (lines 10-13), and brings her back up. He is a classically-bearded Neptune figure with an old serene face. From out of her body streams a flood now of dif- ferent creatures, octopuses, reindeer, kangaroos, 'Who can say all the life/ That left her womb that day?' Squalidozzi can only catch a glimpse of the amazing spill as he bears her back toward the surface. Above, it is a mild and sunlit green lake or pond, grassy at the banks, shaded by willows. Insects whine and hover. The key color now is green. 'And there as it broke to sun/ Her corpse found sleep in the water/ And in the summer depths/ The creatures took their way/ Each to its proper love/ In the height of afternoon/ As the peaceful river went....'" Pynchon (1973, p. 446-447) For reprints of Shulgin's publications, write to: Alexander T. Shulgin 1483 Shulgin Road Lafayette, CA 94549 Be merciful. He is out of many of the older papers, and probably doesn't have reprints of the longer review articles. Don't request reprints of articles that you can get at the library. After each article I have included a number. These are the numbers that Shulgin uses to reference his papers. If you include these it will make it easier for him to locate them. I have the references in troff format. For those not familiar with this format, I include a list of the format commands. \fI start italics \fG start greek \fR end italics or greek \u shift up half line, begin superscript or end subscript \d shift down half line, begin subscript or end superscript \s+2 increase point size by two \s-2 decrease point size by two \*' accent on preceding letter \*: umlaut on preceding letter .XP Pynchon, Thomas. 1973. Gravity's Rainbow. The Viking Press, N.Y. Pp. 760. .XP Shulgin, A. T., S. Bunnell, and T. Sargent. 1961. The psychotomimetic properties of 3,4,5-trimethoxyamphetamine. Nature 189: 10011-1012. 12 .XP _____. 1963. Psychotomimetic agents related to mescaline. Experientia 19: 127. 19 .XP _____. 1963. Composition of the myristicin fraction from oil of nutmeg. Nature 197: 379. 20 .XP _____. 1963. Concerning the pharmacology of nutmeg. Mind 1: 299-302. 23 .XP _____. 1964. 3-methoxy-4,5-methylenedioxy amphetamine, a new psychotomimetic agent. Nature 201: 1120-1121. 29 .XP _____. 1964. Psychotomimetic amphetamines: methoxy 3,4-dialkoxyamphetamines Experientia 20: 366. 30 .XP _____, and H. O. Kerlinger. 1964. Isolation of methoxyeugenol and trans- isoelemicin from oil of nutmeg. Naturwissenschaften 15: 360-361. 31 .XP _____. 1965. Synthesis of the trimethoxyphenylpropenes. Can. J. Chem. 43: 3437-3440. 43 .XP _____. 1966. Possible implication of myristicin as a psychotropic substance Nature 210: 380-384. 45 .XP _____. 1966. The six trimethoxyphenylisopropylamines (trimethoxyamphetamines). J. Med. Chem. 9: 445-446. 46 .XP _____, T. Sargent, and C. Naranjo. 1966. Role of 3,4-dimethoxyphenethylamin in schizophrenia. Nature 212: 1606-1607. 48 .XP _____, T. Sargent, and C. Naranjo. 1967. The chemistry and psychopharmacolo of nutmeg and of several related phenylisopropylamines. \fIIn\fR D. H. Efron [ed.]: Ethnopharmacologic search for psychoactive drugs. U. S. Dept. of H. E. W., Public Health Service Publication No. 1645. Pp. 202-214. Discussion: ibid. pp. 223-229. 49 .XP _____, and T. Sargent. 1967. Psychotropic phenylisopropylamines derived from apiole and dillapiole. Nature 215: 1494-1495. 50 .XP Sargent, T. W., D. M. Israelstam, A. T. Shulgin, S. A. Landaw, and N. N. Finley. 1967. A note concerning the fate of the 4-methoxyl group in 3,4-dimethoxyphenethylamine (DMPEA). Biochem. Biophys. Res. Commun. 29: 126-130. 52 .XP Naranjo, C., A. T. Shulgin, and T. Sargent. 1967. Evaluation of 3,4-methylenedioxyamphetamine (MDA) as an adjunct to psychotherapy. Med. Pharmacol. Exp. 17: 359-364. 53 .XP Shulgin, A. T. 1968. The ethyl homologs of 2,4,5-trimethoxyphenylisopropyl- amine. J. Med. Chem. 11: 186-187. 54 .XP _____, T. Sargent, and C. Naranjo. 1969. Structure activity relationships of one-ring psychotomimetics. Nature 221: 537-541. 57 .XP _____. 1969. Recent developments in cannabis chemistry. J. Psyched. Drugs 2: 15-29. 58 .XP _____. 1969. Psychotomimetic agents related to the catecholamines. J. Psyched. Drugs 2(2): 12-26. 59 .XP _____. 1970. Chemistry and structure-activity relationships of the psychotomimetics. \fIIn\fR: D. H. Efron [ed.]. Psychotomimetic Drugs. Raven Press, New York. Pp. 21-41. 60 .XP _____. 1970. The mode of action of psychotomimetic drugs; some qualitative properties of the psychotomimetics. Neur. Res. Prog. Bull. 8: 72-78. 61 .XP _____. 1970. 4-alkyl-dialkoxy-\fGa\fR-methyl-phenethylamines and their pharmacologically-acceptable salts. U. S. Patent 3,547,999, issued Dec. 15, 1970. 63 .XP _____, T. Sargent, and C. Naranjo. 1971. 4-bromo-2,5-dimethoxyphenyliso- propylamine, a new centrally active amphetamine analog. Pharmacology 5: 103-107. 64 .XP _____. 1971. Chemistry and sources. \fIIn\fR: S. S. Epstein [ed]. Drugs of abuse: their genetic and other chronic nonpsychiatric hazards. The MIT Press, Cambridge, Mass. Pp 3-26. 65 .XP _____. 1971. Preliminary studies of the synthesis of nitrogen analogs of \fGD\fR\u\s-21\s+2\d-THC. Acta Pharm. Suec. 8: 680-681. 66 .XP _____. 1972. Hallucinogens, CNS stimulants, and cannabis. \fIIn\fR: S. J. Mule/*' and H. Brill [eds.]: Chemical and biological aspects of drug dependence. CRC Press, Cleveland, Ohio. Pp. 163-175. 67 .XP _____. 1973. Stereospecific requirements for hallucinogenesis. J. Pharm. Pharmac. 25: 271-272. 68 .XP _____. 1973. Mescaline: the chemistry and pharmacology of its analogs. Lloydia 36: 46-58. 69 .XP _____. 1973. The narcotic pepper - the chemistry and pharmacology of \fIPiper methysticum\fR and related species. Bull. Narc. 25: 59-74. Le poivre stupe\*'fiant - chemie et pharmacologie du \fIPiper methysticum\fR et des espe\*'ces apparente\*'es. Bull. Stupe\*'fiants 25: 61-77. 70 .XP _____, T. Sargent, and C. Naranjo. 1973. Animal pharmacology and human psychopharmacology of 3-methoxy-4,5-methylenedioxyphenylisopropylamine (MMDA). Pharmacology 10: 12-18. 71 .XP _____. Drugs of abuse in the future. Drug abuse in America Vol. 1. pp. 209-236. U.S.G.P.O. 5266-00004. Reprinted: Clin. Tox. 8: 405-456. 72 .XP Kalbhen, D. A., T. Sargent, A. T. Shulgin, G. Braun, H. Stauffer, N. Kusubov, and M. L. Nohr. 1974. Human pharmacodynamics of the psychodysleptic 4-bromo-2,5-dimethoxyphenylisopropylamine labelled with \u82\dBr. IRCS (Int. Res. Comm. Sys.) 2: 1091. 73 .XP Sargent, T., D. A. Kalbhen, A. T. Shulgin, H. Stauffer, and N. Kusubov. 1975 A potential new brain-scanning agent: 4-\u77\dBr-2,5-dimethoxyphenyliso- propylamine (4-Br-DPIA). J. Nucl. Med. 16: 243-245. 74 .XP Shulgin, A. T., and M. F. Carter. 1975. Centrally active phenethylamines. Psychopharm. Commun. 1: 93-98. 75 .XP Sargent, T., D. A. Kalbhen, A. T. Shulgin, G. Braun, H. Stauffer, and N. Kusubov. 1975. \fIIn vivo\fR human pharmacodynamics of the psychodysleptic 4-Br-2,5-dimethoxyphenylisopropylamine labelled with \u82\dBr or \u77\dBr. Neuropharmacology 14: 165-174. 76 .XP _____. 1975. The chemical catalysis of altered states of consciousness. Altered states of consciousness, current views and research problems. The drug abuse council, Washington, D. C. Pp. 123-134. 77 .XP _____. 1975. Drug use and anti-drug legislation. The PharmChem Newsletter 4 (#8). 79 .XP _____, and D. C. Dyer. 1975. Psychotomimetic phenylisopropylamines. 5. 4-alkyl-2,5-dimethoxyphenylisopropylamines. J. Med. Chem. 18: 1201-1204. 80 .XP _____, and C. Helisten. 1975. Differentiation of PCP, TCP, and a contaminating precursor PCC, by thin layer chromatography. Microgram 8: 171-172. 81 .XP Helisten, C., and A. T. Shulgin. The detection of 1-piperidinodydlohexane- carbonitrile contamination in illicit preparations of 1-(1-phenylcyclohexyl) piperidine and 1-(1-(2-thienyl)cyclohexyl)piperidine. J. Chrom. 117: 232-235. 82 .XP Shulgin, A. T. 1976. Psychotomimetic agents. \fIIn\fR: M. Gordon [ed.] Psychopharmacological agents, Vol. 4. Academic Press, New York. Pp. 59-146. 83 .XP _____. 1976. Abuse of the term "amphetamines". Clin. Tox. 9: 351-352. 84 .XP _____. 1976. Profiles of psychedelic drugs. 1. DMT. J. Psychedelic Drugs 8: 167-168. 85 .XP _____. 1976. Profiles of psychedelic drugs. 2. TMA-2. J. Psychedelic Drugs 8: 169. 86 .XP _____, and D. E. MacLean. 1976. Illicit synthesis of phencyclidine (PCP) and several of its analogs. Clin. Tox. 9: 553-560. 87 .XP Nichols, D. E., and A. T. Shulgin. 1976. Sulfur analogs of psychotomimetic amines. J. Pharm. Sci. 65: 1554-1556. 89 .XP Sargent, T., A. T. Shulgin, and N. Kusubov. 1976. Quantitative measurement of demethylation of \u14\dC-methoxyl labeled DMPEA and TMA-2 in rats. Psychopharm. Commun. 2: 199-206. 90 .XP Standridge, R. T., H. G. Howell, J. A. Gylys, R. A. Partyka, and A. T. Shulgin. 1976. Phenylalkylamines with potential psychotherapeutic utility. 1. 2-amino-1-(2,5,-dimethoxy-4-methylphenyl)butane. J. Med. Chem. 19: 1400-1404. 91 .XP _____. 1976. Profiles of psychedelic drugs. 3. MMDA. J. Psychedelic Drugs 8: 331. 92 .XP _____. 1977. Profiles of psychedelic drugs. 4. Harmaline. J. Psychedelic Drugs 9: 79-80. 93 .XP _____. 1977. Profiles of psychedelic drugs. 5. STP. J. Psychedelic Drugs 9: 171-172. 94 .XP Nichols, D. E., A. T. Shulgin, and D. C. Dyer. 1977. Directional lipophilic character in a series of psychotomimetic phenethylamine derivatives. Life Sciences 21: 569-576. 95 .XP Jacob, P. III, G. Anderson III, C. K. Meshul, A. T. Shulgin, and N. Castagnoli Jr. 1977. Mononethylthio analogues of 1-(2,4,5-trimethoxyphenyl) 2-aminopropane. J. Med. Chem. 20: 1235-1239. 96 .XP White, T. J., D. Goodman, A. T. Shulgin, N. Castagnoli Jr., R. Lee, and N. L. Petrakis. 1977. Mutagenic activity of some centrally active aromatic amines in \fISalmonella typhimurium\fR. Mutation Research 56: 199-202. 97 .XP Braun, U., A. T. Shulgin, G. Braun, and T. Sargent III. 1977. Synthesis and body distribution of several iodine-131 labeled centrally acting drugs. J. Med. Chem. 20: 1543-1546. 98 .XP Sargent, T. III, T. F. Budinger, G. Braun, A. T. Shulgin, and U. Braun. 1978. An iodated catecholamine congener for brain imaging and metabolic studies. J. Nucl. Med. 19: 71-76. 99 .XP Shulgin, A. T. 1978. Psychotomimetic drugs: structure-activity relationships. \fIIn\fR: L. L. Iversen, S. D. Iversen, and S. H. Snyder [eds.], Handbook of psychopharmacology, Vol. 11. Plenum Press, New York. Pp. 243-333. .XP Sargent, T. III, G. Braun, U. Braun, T. F. Budinger, and A. T. Shulgin. 1978. Brain and retina uptake of a radio-iodine labeled psychotomimetic in dog and monkey. Commun. Psychopharm. 2: 1-10. 101 .XP Braun, G., A. T. Shulgin, and T. Sargent III. 1978. Synthesis of \u123\dI-labelled 4-iodo-2,5-dimethoxyphenylisopropylamine. J. Labelled Comp. and Radiopharm. 14: 767-773. 102 .XP Murdock, J. E., J. R. Patty, and A. T. Shulgin. 1978. A novel illicit amphetamine laboratory. Microgram 11: 98-101. 103 .XP Anderson, G. M. III, G. Braun, U. Braun, D. E. Nichols, and A. T. Shulgin. 1978. Absolute configuration and psychotomimetic activity. \fIIn\fR: G. Barnett, M. Trsic, and R. Willette [eds.], QuaSAR Research Monograph 22. N.I.D.A. Washington, D.C. Pp. 8-15. 104 .XP Braun, U., G. Braun, P. Jacob III, D. E. Nichols, and A. T. Shulgin. Mescaline analogs: substitutions at the 4-position. \fIIn\fR: G. Barnett, M. Trsic, and R. Willette [eds.], QuaSAR Research Monograph 22. N.I.D.A. Washington, D.C. Pp. 27-37. 105 .XP Partyka, R. A., R. T. Standridge, H. G. Howell, and A. T. Shulgin. 1978. 2-amino-1-(2,5-dimethoxyphenyl)butanes. U.S. Patent 4,105,695, issued Aug. 8, 1978. 106 .XP Shulgin, A. T., and D. E. Nichols. 1978. Characterization of three new psychotomimetics. \fIIn\fR: R. C. Stillman and R. E. Willette [eds.], The psychopharmacology of hallucinogens. Pergamon Press, New York. Pp. 74-83. 107 .XP Glennon, R. A., L. B. Kier, and A. T. Shulgin. 1979. Molecular connectivity analysis of hallucinogenic mescaline analogs. J. Pharm. Sci. 68: 906-907. 108 .XP Shulgin, A. T. 1979. Chemistry of phenethylamines related to mescaline. J. Psychedelic Drugs 11: 41-52. 109 .XP _____. 1979. Profiles of psychedelic drugs. 6. \fGa\fR,O-DMS. J. Psychedelic Drugs 11: 247. 110 .XP _____. 1979. Profiles of psychedelic drugs. 7. Mescaline. J. Psychedelic Drugs 11: 355. 111 .XP Standridge, R. T., H. G. Howell, H. A. Tilson, J. H. Chamberlain, H. M. Holava, J. A. Gylys, R. A. Partyka, and A. T. Shulgin. 1980. Phenylalkylamines with potential psychotherapeutic utility. 2. Nuclear substituted 2-amino-1-phenylbutanes. J. Med. Chem. 23: 154-162. 112 .XP Braun, U., A. T. Shulgin, and G. Braun. 1980. Centrally active N-substituted analogs of 3,4-methylenedioxyphenylisopropylamine (3,4-methylenedioxyamphetamine). J. Pharm. Sci. 69: 192-195. 113 .XP Kantor, R. E., S. D. Dudlettes, and A. T. Shulgin. 1980. 5-methoxy- \fGa\fR-methyltryptamine (\fGa\fR,O-dimethylserotonine) a hallucinogenic homolog of serotonin. Biol. Psychiat. 15: 349-352. 114 .XP Shulgin, A. T. 1980. Profiles of psychedelic drugs. 8. psilocybin. J. Psychedelic Drugs 12: 79. 115 .XP Braun, U., A. T. Shulgin, and G. Braun. 1980. Pru\*:fung auf Aktivita\*:t und Analgesia von N-substituierten Analogen des Amphetamin- Derivates 3,4-Methylendioxyphenylisopropylamin. Arzneim. Forsch. 30: 825-830. 116 .XP Shulgin, A. T. 1980. Profiles of psychedelic drugs. 9. LSD. J. Psychedelic Drugs 12: 173-174. 117 .XP _____. 1981. Hallucinogens. \fIIn\fR: M. E. Wolff [ed.], Burger's medicinal chemistry. Wiley & Co. Pp. 1109-1137. .XP _____. 1981. Profiles of psychedelic drugs. 10. DOB. J. Psychoactive Drugs 13: 99. 119 .XP _____, and M. F. Carter. 1981. N,N-diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity. Commun. Psychopharmacol. 4: 363-369. 120 .XP Jacob, P., and A. T. Shulgin. 1981. Sulfur analogues of psychotomimetic agents. Monothio analogues of mescaline and isomescaline. J. Med. Chem. 24: 1348. 121 .XP Domelsmith, L. N., T. A. Eaton, K. N. Houk, G. M. Anderson, R. A. Glennon, A. T. Shulgin, N. Castagnoli, and P. A. Kollman. 1981. Photoelectron spectra of psychotropic drugs. 6. Relationships between physical properties and pharmacological actions of amphetamine analogues. J. Med. Chem. 24: 1414. 122 .XP Shulgin, A. T. 1981. Chemistry of psychotomimetics. \fIIn\fR: F. Hoffmeister and G. Stille [eds.], Handbook of experimental pharmacology, Vol. 55/III. Springer-Verlag, Berlin Heidelberg. Pp. 3-29. .XP _____. 1981. Profiles of psychedelic drugs. 11. Bufotenine. J. Psychoactive Drugs 13: 389. 124 .XP _____, and P. Jacob. 1982. Potential misrepresentation of 3,4-methylene- dioxyamphetamine (MDA). A toxicological warning. J. Anal. Tox. 6: 71. 127 .XP _____, and P. Jacob. 1982. 1-(3,4-methylenedioxyphenyl)-3-aminobutane: a potential toxicological problem. J. Toxicol. - Clin. Toxicol. 19: 109. 12 .XP Jacob, P., and A. T. Shulgin. 1983. Sulfur analogues of psychotomimetic agents. 2. Analogues of (2,5-dimethoxy-4-methylphenyl)- and (2,5- dimethoxy-4-ethylphenyl)-isopropylamine. J. Med. Chem. 26: 746. 130 .XP Shulgin, A. T. 1983. Twenty years on an ever-changing quest. \fIIn\fR: L. Grinspoon and J. B. Bakalar [eds.], Psychedelic Reflections. Human Sciences Press, New York. 131 .XP Sargent, T., A. T. Shulgin, and C. A. Mathis. 1982. New iodinated amphetamines by rapid synthesis for use as brain blood flow indicators. J. Lab. Cmpds. and Radiopharm. 19: 1307. 132 .XP Jacob, P., and A. T. Shulgin. 1984. Sulfur analogues of psychotomimetic agents. 3. The ethyl homologues of mescaline and their monothio analogues. J. Med. Chem. 27: 881-888. 133 .XP Sargent, T., A. T. Shulgin, and C. A. Mathis. 1984. Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography. J. Med. Chem. 27: 1071-1077. 135 .XP Repke, D. B., D. B. Grotjahn, and A. T. Shulgin. 1985. Psychotomimetic N-methyl-N-isopropyltryptamines. Effects of variation of aromatic oxygen substituents. J. Med. Chem. 28: 892. 136 .XP Shulgin, A. T. 1985. What is MDMA? PharmChem Newsletter 14: 3 (May-June, #3). 137 .XP Lemaire, D., P. Jacob, and A. T. Shulgin. 1985. Ring substituted beta-methoxyphenethylamines: a new class of psychotomimetic agents active in man. J. Pharm. Pharmacol. 37: 575. 138 .XP Mathis, C. A., T. Sargent, and A. T. Shulgin. 1985. Iodine-122 labeled amphetamine derivatives with potential for PET brain blood-flow studies. J. Nucl. Med. 26: 1295. 139 .XP _____, _____, and _____. 1986. Synthesis of 122-I and 125-I-labeled- \fImeta\fR-dimethoxy-N,N-dimethyliodophenylisopropylamines. J. Labelled Comp. Radiopharm. 23: 115. 140 .XP Shulgin, A. T., L. A. Shulgin, and P. Jacob. 1986. A protocol for the evaluation of new psychoactive drugs. Methods and Findings in Experimental and Clinical Pharmacology 8: 313. 141 .XP Nichols, D. E., A. J. Hoffman, R. A. Oberlender, P. Jacob, and A. T. Shulgin. 1986. Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class. J. Med. Chem. 29: 2009. 143 .XP Mathis, C. A., A. T. Shulgin, Y. Yano, and T. Sargent. 1986. \u18\dF- labelled N,N-dimethylamphetamine analogues for brain imaging studies. Appl. Radiat. Isot. 37: 865. 144 .XP Shulgin, A. T. 1986. The background and chemistry of MDMA. J. Psychoactive Drugs 18: 291-304. 145 .XP Sargent, T. W., A. T. Shulgin, and C. A. Mathis. 1987. Rapid brain scanning pharmaceutical. U. S. Patent 4,647,446. 146 .XP McKenna, D. J., C. A. Mathis, A. T. Shulgin, T. Sargent, and J. M. Saavedra. 1987. Autoradiographic localization of binding sites for \u125\dI-DOI, a new psychotomimetic radioligand, in the rat brain. Eur. J. Pharmacol. 137: 289-290. 147 .XP Shulgin, A. T. 1987. The 'social-chemistry' of pharmacological discovery. Social Pharmacology 1: 279-290. 148 .XP _____. 1987. Reference information on MDMA. Analog 9: #4 (page 10). 149 .XP _____. 1988. DIPT: the distortion of music. Reality Hackers #6 (Winter 1988) p. 27. 152. .XP _____. 1988. THE CONTROLLED SUBSTANCES ACT: A resource manual of the current status of the federal drug laws. 383 pp., published in Lafayette, California 94549 April 1988. 154 .XP _____. In press. History of MDMA. \fIIn\fR: S. Peroutka [ed.], MDMA: "Ecstasy" and human neurotoxin? Kluwer Academic Publishers, Norwell, MA, 02061. ------end forwarded message----------